![Genmab A/S Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/gmab.png?tr=w-200)
Genmab A/S
NASDAQ:GMAB
![Genmab A/S Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/gmab.png)
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
24.85
42.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Realty Income Corp
NYSE:O
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/gmab.png)
Intrinsic Value
Genmab A/S operates as an international biotechnology company. [ Read More ]
The intrinsic value of one
GMAB
stock under the Base Case scenario is
39.58
USD.
Compared to the current market price of 28.38 USD,
Genmab A/S
is
Undervalued by 28%.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/gmab.png?tr=w-200)
Valuation Backtest
Genmab A/S
Run backtest to discover the historical profit from buying and selling
GMAB
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Genmab A/S
Current Assets | 34.4B |
Cash & Short-Term Investments | 29.6B |
Receivables | 4.7B |
Other Current Assets | 106m |
Non-Current Assets | 2.3B |
Long-Term Investments | 153m |
PP&E | 1.9B |
Intangibles | 23m |
Other Non-Current Assets | 275m |
Current Liabilities | 2.8B |
Other Current Liabilities | 2.8B |
Non-Current Liabilities | 1.4B |
Long-Term Debt | 918m |
Other Non-Current Liabilities | 506m |
Earnings Waterfall
Genmab A/S
Revenue
|
17.8B
DKK
|
Cost of Revenue
|
-4.6B
DKK
|
Gross Profit
|
13.2B
DKK
|
Operating Expenses
|
-7.5B
DKK
|
Operating Income
|
5.7B
DKK
|
Other Expenses
|
-234m
DKK
|
Net Income
|
5.5B
DKK
|
Free Cash Flow Analysis
Genmab A/S
DKK | |
Free Cash Flow | DKK |
GMAB Profitability Score
Profitability Due Diligence
Genmab A/S's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/gmab.png)
Score
Genmab A/S's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
GMAB Solvency Score
Solvency Due Diligence
Genmab A/S's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/gmab.png)
Score
Genmab A/S's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GMAB Price Targets Summary
Genmab A/S
According to Wall Street analysts, the average 1-year price target for
GMAB
is 165.42 USD
with a low forecast of 7.68 USD and a high forecast of 509.45 USD.
Price Appreciation
GMAB Price
Genmab A/S
Average Annual Return | 26.78% |
Standard Deviation of Annual Returns | 38.32% |
Max Drawdown | -49% |
Market Capitalization | 18B USD |
Shares Outstanding | 634 659 008 |
Percentage of Shares Shorted | 0.17% |
Company Profile
![Genmab A/S Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/gmab.png?tr=w-200)
![Genmab A/S Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/gmab.png?tr=w-200)
Country
Industry
Market Cap
Dividend Yield
Description
Genmab A/S operates as an international biotechnology company. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Contact
IPO
Employees
Officers
The intrinsic value of one
GMAB
stock under the Base Case scenario is
39.58
USD.
Compared to the current market price of 28.38 USD,
Genmab A/S
is
Undervalued by 28%.